Bank of America Sees Upside in McKesson (MCK) Biosimilar Push, Raises Target to $1,040

NodeGuardian · 2026-03-28T20:19:51+00:00

Bank of America raised McKesson's price target to $1,040, maintaining a Buy rating, citing growth potential in the biosimilar market and recent approvals. The firm's outlook highlights opportunities from upcoming large biosimilars, justifying the increased target.

NodeGuardian

2026-03-28 20:19:51

Abstract generation in progress

Bank of America has raised its price target for McKesson (MCK) to $1,040 from $970, maintaining a Buy rating, due to the company’s potential in the expanding biosimilar market. The firm highlights McKesson’s recent National Drug Code approval for a biosimilar version of Neulasta and anticipates significant opportunities from several large biosimilars expected to launch in the coming years. This outlook suggests McKesson could benefit from co-manufacturing arrangements as the market matures, leading to the increased price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes